(E00955) Stock Price

Morita Pharmaceutical Industries is a pharmaceutical company whose core business is the manufacturing and sales of over-the-counter (OTC) medicines, quasi-drugs, and nutritional function foods. The company handles both in-house manufactured products and purchased inventory, and operates its pharmaceutical business alongside its consolidated subsidiary Vitaex Pharmaceutical Industries. The company's operations are concentrated in a single pharmaceutical-related business segment.

The company's revenue structure consists of sales of in-house manufactured medicines and sales of purchased products from subsidiaries and other companies. Additionally, the company engages in contract manufacturing for its consolidated subsidiary Vitaex Pharmaceutical Industries, building relationships through both manufacturing services and product procurement. This approach enables the company to realize synergistic effects within the group.

The company's main products include in-house manufactured items such as "Tachikawa Electrolyzed Calcium," "Pediatric Nova Cough Syrup," and "Mycos Dash." For purchased and resold products, the company handles items including "Tablet Lumin A" and "Vitaex GO." The subsidiary Vitaex Pharmaceutical Industries is responsible for manufacturing and selling products such as "Vitaex GO" and "Oridin P Oral Liquid," providing a diverse pharmaceutical product lineup across the group.

Morita Pharmaceutical Industries aims for sustained growth in the self-medication market and has established clear financial targets. The company has set numerical goals of return on equity (ROE) of 10% or higher and equity ratio of 70% or higher, balancing profitability with financial stability. These metrics demonstrate a distinctive approach to presenting a clear growth trajectory for investors.

The company's core strategy focuses on developing differentiated products centered on foundational health pharmaceuticals. In addition to flagship products such as "Tachikawa Electrolyzed Calcium," "Lumin A," and "Vitaex," the company is driving sales expansion of nutritional functional foods containing "placenta extract" and "liver extract." This product portfolio aligns with the trend of extending healthy life expectancy and benefits from tailwinds created by self-medication tax incentives, strengthening the company's market presence.

The company employs a multifaceted approach to business expansion. While expanding sales channels, it is strengthening private brand product development tailored to customer needs and contract manufacturing operations. This strategy—securing stable revenue through manufacturing contracts in addition to selling proprietary branded products—is noteworthy for investors.

Regarding technological innovation, the company actively promotes joint research through industry-academia collaboration. Positioning research and development capabilities as a key source of competitive advantage in response to a challenging market environment marked by intensifying drugstore competition and expanding internet sales, the company maintains a basic policy of stable supply of high-quality, safe products while continuing investment in technology development aimed at creating new value.